{"id":450,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"},"modified":"2026-08-28T07:42:46","modified_gmt":"2026-08-28T07:42:46","slug":"mapa-de-evidencias-sobre-o-status-do-desenvolvimento-do-retatrutide-em-2026","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/pt-br\/retatrutide-development-status-2026-evidence-map\/","title":{"rendered":"Status de desenvolvimento de Retatrutide em 2026: um mapa de evid\u00eancias para pesquisadores"},"content":{"rendered":"
Os compostos em est\u00e1gio de desenvolvimento criam um problema recorrente de precis\u00e3o SEO: an\u00fancios de testes, status de registro, relat\u00f3rios de confer\u00eancias, artigos de peri\u00f3dicos e aprova\u00e7\u00f5es s\u00e3o frequentemente combinados em um \u00fanico cronograma. Este mapa de evid\u00eancias mant\u00e9m esses marcos separados para a retatrude.<\/p>
Principais conclus\u00f5es<\/h2>
Os resultados da fase 2 revisados \u200b\u200bpor pares e um registro de registro 3 da fase conclu\u00edda s\u00e3o objetos de evid\u00eancia diferentes.<\/li>
ClinicalTrials.gov ainda n\u00e3o mostra resultados publicados para TRIUMPH-1, enquanto agora existem divulga\u00e7\u00f5es de primeira linha do patrocinador 2026; esses objetos de evid\u00eancia s\u00e3o relatados separadamente abaixo.<\/li>
O status regulat\u00f3rio deve ser verificado em rela\u00e7\u00e3o aos registros FDA, e n\u00e3o inferido a partir da cobertura da m\u00eddia ou da disponibilidade do cat\u00e1logo.<\/li><\/ul><\/div><\/div>Ilustra\u00e7\u00e3o conceitual de pesquisas multirreceptores; nenhum resultado de teste ou apresenta\u00e7\u00e3o do produto \u00e9 retratado.<\/figcaption><\/figure>
A escada da evid\u00eancia<\/h2>
Um registro de ensaio responde a quest\u00f5es de protocolo e status: o que foi planejado, quem era eleg\u00edvel, quais resultados foram designados e se o recrutamento ou o acompanhamento foram conclu\u00eddos. Um artigo de peri\u00f3dico responde a um conjunto diferente de perguntas ap\u00f3s an\u00e1lise de dados e revis\u00e3o por pares. Um registro de aprova\u00e7\u00e3o FDA adiciona uma determina\u00e7\u00e3o regulat\u00f3ria independente para um produto espec\u00edfico.<\/p>
Publicado<\/strong>Ensaio de obesidade de fase 2 com resultados revisados \u200b\u200bpor pares<\/span><\/div>
Registrado\/conclu\u00eddo<\/strong>Registro 3 da fase TRIUMPH-1; informa\u00e7\u00f5es de status e protocolo<\/span><\/div>
Patrocinador relatado<\/strong>Resultados 2026 da Fase 3; ainda n\u00e3o h\u00e1 relat\u00f3rios completos revisados \u200b\u200bpor pares<\/span><\/div>
ClinicalTrials.gov<\/strong>TRIUMPH-1 ainda exibe Nenhum resultado publicado<\/span><\/div>
N\u00e3o estabelecido<\/strong>Aprova\u00e7\u00e3o FDA para retatrutida<\/span><\/div><\/div><\/div>
Como atualizar esta p\u00e1gina com responsabilidade<\/h2>
Quando um registro for alterado, registre a data de atualiza\u00e7\u00e3o e descreva apenas o campo alterado. Quando os resultados aparecerem, vincule o registro de resultados ou a publica\u00e7\u00e3o revisada por pares e distinga os par\u00e2metros pr\u00e9-especificados das an\u00e1lises explorat\u00f3rias. Quando o status regulat\u00f3rio mudar, substitua \u2013 e n\u00e3o apenas anexe \u2013 a antiga declara\u00e7\u00e3o de status.<\/p>
N\u00e3o atualize a data do artigo sem altera\u00e7\u00f5es substanciais nas evid\u00eancias. A orienta\u00e7\u00e3o do Google que prioriza as pessoas alerta explicitamente contra a altera\u00e7\u00e3o de datas apenas para fazer o conte\u00fado parecer novo.<\/p>
Linha superior da Fase 3 relatada pelo patrocinador 2026<\/h2>
Lilly relatou resultados principais para TRIUMPH-1 em maio 21, 2026: nas semanas 80, o patrocinador relatou altera\u00e7\u00e3o m\u00e9dia de peso de \u221228.3% para o grupo 12 mg. Em julho 23, 2026, Lilly relatou mudan\u00e7as m\u00e9dias de at\u00e9 \u221220.8% em TRIUMPH-2 e \u221222.6% em TRIUMPH-3. Estas s\u00e3o divulga\u00e7\u00f5es do patrocinador principal, n\u00e3o m\u00f3dulos de resultados do ClinicalTrials.gov ou relat\u00f3rios completos revisados \u200b\u200bpor pares; m\u00e9todos detalhados, decis\u00f5es de an\u00e1lise e tabelas completas de eventos adversos ainda exigem registros completos. ClinicalTrials.gov continuou a mostrar \u201cNenhum resultado publicado\u201d para TRIUMPH-1 nesta revis\u00e3o.<\/p>
Implica\u00e7\u00f5es para p\u00e1ginas de pesquisa de cat\u00e1logo<\/h2>
Uma p\u00e1gina de cat\u00e1logo pode usar o cronograma de desenvolvimento para orientar os pesquisadores, mas deve manter a separa\u00e7\u00e3o entre as evid\u00eancias da literatura e a qualidade do lote. Deve estar vinculado aos m\u00f3dulos de especifica\u00e7\u00f5es e evid\u00eancias da fam\u00edlia e deve indicar que o material n\u00e3o \u00e9 para uso humano ou veterin\u00e1rio.<\/p>","protected":false},"excerpt":{"rendered":"
Um mapa de evid\u00eancias 2026 separando dados publicados da fase retatrutide 2, registros de estudo da fase completa 3, resultados n\u00e3o publicados e status regulat\u00f3rio.<\/p>","protected":false},"author":1,"featured_media":620,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"359","pim_article_type":"Development-status evidence map","pim_evidence_level":"Trial registry, peer-reviewed phase 2 evidence and FDA status","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Retatrutide phase 2 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\",\"note\":\"Peer-reviewed outcomes.\"},{\"title\":\"TRIUMPH-1 ClinicalTrials.gov record\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\",\"note\":\"Protocol and current study-status record.\"},{\"title\":\"FDA current information on retatrutide status\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Authoritative regulatory boundary.\"},{\"title\":\"TRIUMPH-1 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\",\"note\":\"Lilly primary-sponsor news release, May 21, 2026; not a peer-reviewed full report.\"},{\"title\":\"TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-successful-two-additional\",\"note\":\"Lilly primary-sponsor news release, July 23, 2026; detailed results remain pending.\"},{\"title\":\"Google guidance on people-first content and substantive date changes\",\"url\":\"https:\/\/developers.google.com\/search\/docs\/fundamentals\/creating-helpful-content\",\"note\":\"Official Google Search Central guidance cited for the editorial-update statement.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-450","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\n
Retatrutide Development Status in 2026: An Evidence Map for Researchers - NHD<\/title>\n<meta name=\"description\" content=\"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/pt-br\/mapa-de-evidencias-sobre-o-status-do-desenvolvimento-do-retatrutide-em-2026\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Development Status in 2026: An Evidence Map for Researchers\" \/>\n<meta property=\"og:description\" content=\"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/pt-br\/mapa-de-evidencias-sobre-o-status-do-desenvolvimento-do-retatrutide-em-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:42:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Retatrutide Development Status in 2026: An Evidence Map for Researchers\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\",\"name\":\"Retatrutide Development Status in 2026: An Evidence Map for Researchers - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"description\":\"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retatrutide Development Status in 2026: An Evidence Map for Researchers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/pt-br\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Status de desenvolvimento de Retatrutide em 2026: um mapa de evid\u00eancias para pesquisadores - NHD","description":"Um mapa de evid\u00eancias 2026 separando dados publicados da fase retatrutide 2, registros de estudo da fase completa 3, resultados n\u00e3o publicados e status regulat\u00f3rio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/pt-br\/mapa-de-evidencias-sobre-o-status-do-desenvolvimento-do-retatrutide-em-2026\/","og_locale":"pt_BR","og_type":"article","og_title":"Retatrutide Development Status in 2026: An Evidence Map for Researchers","og_description":"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.","og_url":"https:\/\/nhdbio.com\/pt-br\/mapa-de-evidencias-sobre-o-status-do-desenvolvimento-do-retatrutide-em-2026\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:42:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Retatrutide Development Status in 2026: An Evidence Map for Researchers","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/","url":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/","name":"Status de desenvolvimento de Retatrutide em 2026: um mapa de evid\u00eancias para pesquisadores - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","description":"Um mapa de evid\u00eancias 2026 separando dados publicados da fase retatrutide 2, registros de estudo da fase completa 3, resultados n\u00e3o publicados e status regulat\u00f3rio.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Retatrutide Development Status in 2026: An Evidence Map for Researchers"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mat\u00e9rias-primas pept\u00eddicas e s\u00edntese personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipe T\u00e9cnica NHD","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"A equipe t\u00e9cnica NHD mant\u00e9m documenta\u00e7\u00e3o de cat\u00e1logo de uso em pesquisa e resumos de evid\u00eancias. Os artigos revisados \u200b\u200bvinculam-se a artigos revisados \u200b\u200bpor pares, registros de ensaios e registros regulat\u00f3rios, ret\u00eam resultados nulos e limita\u00e7\u00f5es de estudos e distinguem interven\u00e7\u00f5es publicadas de materiais de cat\u00e1logo. O desenho assistido por AI pode ser usado para estrutura; os links de origem e os limites das evid\u00eancias permanecem vis\u00edveis. Este trabalho n\u00e3o \u00e9 uma revis\u00e3o independente por pares ou aconselhamento m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/pt-br\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/comments?post=450"}],"version-history":[{"count":3,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/450\/revisions"}],"predecessor-version":[{"id":530,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/450\/revisions\/530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media\/620"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media?parent=450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/categories?post=450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/tags?post=450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Pesquisador](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png\")